Latest news with #Roche
Globe and Mail
14 hours ago
- Business
- Globe and Mail
Follicular Lymphoma Market Forecast 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Revenue, Statistics, Prevalence and Companies by DelveInsight
Follicular Lymphoma Market Growth Accelerates at a CAGR of 6% During the Forecast Period (2025-2034). Increased awareness of the disease has led to a higher number of treated cases, contributing to market growth. The rising number of clinical trials focused on follicular lymphoma are a significant driver of its market's expansion. Follicular Lymphoma Companies are Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, Abbvie, Novartis, Innovent Biologics, Regeneron, Genentech, Eli Lilly, more. (Albany, USA) DelveInsight's " Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2034 ' report offers an in-depth understanding of the Follicular Lymphoma, historical and forecasted epidemiology as well as the Follicular Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The Follicular Lymphoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Follicular Lymphoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Follicular Lymphoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Follicular Lymphoma market. Key highlights of the Follicular Lymphoma Market Report: The Follicular Lymphoma market size was valued ~USD 1,082 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In February 2025, Regeneron Pharmaceuticals announced the resubmission of the Biologics License Application (BLA) for odronextamab in relapsed/refractory follicular lymphoma to the FDA. The company expects a decision from the FDA in the second half of 2025. In February 2025, Genmab A/S (Nasdaq: GMAB) announced that the Japan Ministry of Health, Labour, and Welfare has approved EPKINLY Registered (epcoritamab) for treating patients with relapsed or refractory follicular lymphoma (FL; Grades 1 to 3A) who have undergone two or more prior treatments. This approval makes EPKINLY the first and only subcutaneously administered T-cell engaging bispecific antibody approved in Japan for both relapsed or refractory FL and large B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma, after two or more prior therapies. In January 2025, CRISPR Therapeutics announced plans to collaborate with regulatory authorities to determine the next steps for CTX112 in B-cell malignancies, with an update anticipated by mid-2025. In September 2024, The FDA granted Priority Review status to the Biologics License Application (BLA) for odronextamab, intended for the treatment of adults with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma (DLBCL) who have not responded to at least two prior systemic therapies. In 2024, approximately 35,000 cases of follicular lymphoma were diagnosed across the 7MM. In 2024, the United States generated around USD 1,082 million in revenue. In 2024, Germany represented the largest market size among the EU4 and the UK, with an estimated value of around USD 108 million. In 2024, Spain had the smallest market size among the EU4 and the UK, with an estimated value of around USD 61 million. In 2024, the United States had the highest number of Follicular Lymphoma cases among the 7MM, with approximately 17,000 cases. This number is expected to rise by 2034. In 2024, the 60-80 age group had the highest incidence of follicular lymphoma, with around 9,000 cases, followed by the 40-59 age group with approximately 4,000 cases. In 2024, stage IV follicular lymphoma cases accounted for approximately 34% of all cases. In 2024, the incidence of follicular lymphoma in the EU4 and the UK was approximately 14,000, with Germany reporting the highest number of cases. Key Follicular Lymphoma Companies: Roche, BeiGene, Kite Pharma, Incyte Corporation, AstraZeneca, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly and Company, ADC Therapeutics S.A, BeiGene, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others Key Follicular Lymphoma Therapies: LUNSUMIO (mosunetuzumab), BRUKINSA (zanubrutinib), YESCARTA, MONJUVI (tafasitamab), AZD0486, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others The Follicular Lymphoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Follicular Lymphoma pipeline products will significantly revolutionize the Follicular Lymphoma market dynamics. Follicular Lymphoma Overview Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma that arises from B-lymphocytes, a type of white blood cell essential for the immune system. Follicular Lymphoma typically originates in the lymph nodes but can also affect the bone marrow and spleen. This form of lymphoma is characterized by the formation of abnormal follicles within lymph nodes, leading to painless swelling, fatigue, night sweats, and unexplained weight loss. Follicular Lymphoma most commonly affects adults over the age of 60 and is usually diagnosed through a combination of physical examination, blood tests, imaging studies, and biopsy. Genetic testing may also be used to identify specific mutations, such as the BCL2 gene rearrangement, which is often associated with this disease. Follicular Lymphoma treatment options vary depending on the stage and symptoms, ranging from active surveillance in early stages to targeted therapies, immunotherapy, chemotherapy, and radiation therapy in more advanced or symptomatic cases. While Follicular Lymphoma is generally considered incurable, it is highly treatable, and many patients live for years with proper disease management. Follicular Lymphoma research continues to advance, with clinical trials exploring novel therapies aimed at improving outcomes and extending progression-free survival, making the future more hopeful for affected patients. Follicular Lymphoma Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Follicular Lymphoma Epidemiology Segmentation: The Follicular Lymphoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into: Total Prevalence of Follicular Lymphoma Prevalent Cases of Follicular Lymphoma by severity Gender-specific Prevalence of Follicular Lymphoma Diagnosed Cases of Episodic and Chronic Follicular Lymphoma Download the report to understand which factors are driving Follicular Lymphoma epidemiology trends @ The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Follicular Lymphoma market or expected to get launched during the study period. The analysis covers Follicular Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Follicular Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Follicular Lymphoma Therapies and Key Companies LUNSUMIO (mosunetuzumab): Roche BRUKINSA (zanubrutinib): BeiGene YESCARTA: Kite Pharma MONJUVI (tafasitamab): Incyte Corporation AZD0486: AstraZeneca Abexinostat: Xynomic Pharmaceuticals ME-401: MEI Pharma Tisagenlecleucel: Novartis Parsaclisib (IBI376): Innovent Biologics Odronextamab: Regeneron Mosunetuzumab: Genetech Abexinostat: Xynomic Pharma Rituximab IV: Roche Atezolizumab (MPDL3280A) [TECENTRIQ]: Hoffmann-La Roche Enzastaurin: Eli Lilly and Company Loncastuximab tesirine: ADC Therapeutics S.A Zanubrutinib: BeiGene Bendamustine: Cephalon Tazemetostat: Epizyme, Inc. ibrutinib: Pharmacyclics LLC. Obatoclax mesylate: Gemin X Ibrutinib: AbbVie IXAZOMIB: Millennium Pharma To know more about Follicular Lymphoma companies working in the treatment market, visit @ Follicular Lymphoma Medication, Manufacturers and Therapeutic Assessment Follicular Lymphoma Market Outlook DelveInsight estimates that the US market size for follicular lymphoma is expected to grow from USD 1 billion in 2024 at a significant CAGR by 2034. The follicular lymphoma market is experiencing steady growth, driven by rising incidence rates, increasing awareness, and advancements in targeted therapies such as monoclonal antibodies and CAR-T cell treatments. The aging global population further contributes to market expansion. Additionally, ongoing clinical trials and approvals of novel agents are expected to boost market opportunities in the coming years. The anticipated launch of these emerging therapies for follicular lymphoma are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the follicular lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. Scope of the Follicular Lymphoma Market Report Study Period: 2020-2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Follicular Lymphoma Companies: AbbVie (NYSE: ABBV), Genentech (subsidiary of Roche), Xynomic Pharma (OTC: XYNM), Regeneron (NASDAQ: REGN), Epizyme, Inc. (formerly NASDAQ: EPZM), ADC Therapeutics S.A (NYSE: ADCT), Kite Pharma (subsidiary of Gilead Sciences), Eli Lilly and Company (NYSE: LLY), Cephalon (acquired by Teva), Innovent Biologics (HKEX: 1801), Incyte Corporation (NASDAQ: INCY), Novartis (SWX: NOVN), MEI Pharma (NASDAQ: MEIP), AstraZeneca (LSE: AZN), BeiGene (NASDAQ: BGNE; HKEX: 6160), Millennium Pharma (subsidiary of Takeda), Roche (SWX: ROG), Gemin X (acquired by Cephalon), Pharmacyclics LLC. (formerly NASDAQ: PCYC), Xynomic Pharmaceuticals (OTC: XYNM), and others. Key Follicular Lymphoma Therapies: LUNSUMIO (mosunetuzumab), BRUKINSA (zanubrutinib), YESCARTA, MONJUVI (tafasitamab), AZD0486, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Follicular Lymphoma Unmet Needs, KOL's views, Analyst's views, Follicular Lymphoma Market Access and Reimbursement Follicular Lymphoma Clinical Trials and FDA Approvals Table of Contents 1. Follicular Lymphoma Market Report Introduction 2. Executive Summary for Follicular Lymphoma 3. SWOT analysis of Follicular Lymphoma 4. Follicular Lymphoma Patient Share (%) Overview at a Glance 5. Follicular Lymphoma Market Overview at a Glance 6. Follicular Lymphoma Disease Background and Overview 7. Follicular Lymphoma Epidemiology and Patient Population 8. Country-Specific Patient Population of Follicular Lymphoma 9. Follicular Lymphoma Current Treatment and Medical Practices 10. Follicular Lymphoma Unmet Needs 11. Follicular Lymphoma Emerging Therapies 12. Follicular Lymphoma Market Outlook 13. Country-Wise Follicular Lymphoma Market Analysis (2020-2034) 14. Follicular Lymphoma Market Access and Reimbursement of Therapies 15. Follicular Lymphoma Market Drivers 16. Follicular Lymphoma Market Barriers 17. Follicular Lymphoma Appendix 18. Follicular Lymphoma Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Euractiv
a day ago
- Business
- Euractiv
Irish AI start-up targets chemotherapy bottlenecks with remote assessment platform
Dublin - Irish health-tech start-up eAltra is poised to transform chemotherapy care delivery with an AI-powered remote assessment platform that promises to cut costs, reduce patient wait times, and ease pressure on overstretched oncology departments. The company, a spin-out from Trinity College Dublin's ADAPT Centre and backed by Enterprise Ireland as a High Potential Start-Up (HPSU), has demonstrated the efficacy of its conversational AI tool in a six-month pilot study conducted in partnership with Health Innovation Hub Ireland (HIHI) and Tallaght University Hospital (TUH). The platform enables patients to complete chemotherapy toxicity assessments remotely in under six minutes, a process that traditionally requires in-person consultations. According to the study, the tool not only improves patient experience but also delivers measurable gains in clinical efficiency and cost savings. The study found that, 'For patients, eAltra's pre-appointment remote assessment, completed in under six minutes, reduces unnecessary travel and optimises appointment scheduling – timed chemo production ensures treatment is ready when a patient arrives, eliminating wait times by up to two hours.' Patients reported high satisfaction with the tool's usability and clarity. Clinical teams also stand to benefit. The study reported a minimum productivity gain of 3.5 hours per treatment day, equating to 20 minutes saved per patient. Importantly, the AI chatbot achieved a 98 per cent agreement rate with nurse-led assessments, the current gold standard. Scalable cost-savings From a financial perspective, the implications are significant. In a hospital treating 200 patients annually, the tool could generate savings of €27,300 per nurse, rising to €55,000 with two clinical nurse specialists. Additional savings are anticipated from reduced paper usage. The platform is designed for seamless integration with existing health IT infrastructure. It complies with HL7 standards and is interoperable with national systems including the National Cancer Information System, Cerner/Oracle Health, and EPIC. Sustainability is another key advantage. By enabling remote care, eAltra reduces patient travel and associated emissions. With healthcare accounting for five per cent of global travel, the shift to digital engagement offers a meaningful reduction in carbon footprint. Denis Roche, founder and CEO of eAltra explained that, 'eAltra is a spin out company of Trinity College Dublin and was awarded High Potential Startup status by Enterprise Ireland.' Roche explained how, 'Health Innovation Hub Ireland has been supporting our development throughout these milestones. The clinical access, study design support and pilot management they have provided has contributed to our product development and market positioning. We are hugely ambitious for eAltra both at home and abroad and the HIHI pilot result provide significant evidence of efficacy, useability, impact and patient satisfaction.' AI reshaping healthcare Eimear Galvin, HIHI Dublin Manager, highlighted how AI is reshaping healthcare She said: 'These study results show that eAltra improves patient care, provides cost savings and increases productivity by streamlining processes and minimising delays in systemic anti-cancer therapy, in this case chemotherapy.' Galvin added that by enabling remote assessments just 24 hours pre-appointment, unnecessary travel and associated costs are eliminated, ensuring timely rescheduling when required. She explained that, 'Timed chemotherapy production aligns drug preparation with patient arrival, reducing wait times by up to two hours and optimising pharmacy workflows.' The announcement comes as HIHI launches a national competition, ' to identify and pilot AI-driven healthcare innovations. The call is open to companies, researchers, and clinicians until 28 August, with selected projects to be trialled in clinical settings across Ireland. More information is available at Digital care policy advances eAltra's innovation aligns closely with Ireland's national AI strategy. As the Department of Enterprise, Trade and Employment stated in its 2024 strategy refresh: 'AI presents opportunities completely unlike those we have experienced before with previous technological advancements, in terms of their potentially transformative impact for our collective good.' Ireland's 'Digital for Care' framework also underpins eAltra's approach. The framework sets out a roadmap to digitally transform health services in Ireland and improve access for patients, and at the European level, the European Commission has noted that, 'AI is emerging not just as a tool but as a transformative force reshaping healthcare delivery.' The Commission has said that 'AI-driven personalised treatment plans can complement traditional approaches by offering more targeted and effective care, improving patient outcomes while also helping to reduce the financial burden on healthcare systems.' By Brian Maguire
Irish Daily Mirror
a day ago
- Sport
- Irish Daily Mirror
Ben Healy follows Elliott, Kelly and Roche in wearing yellow jersey
BEN Healy has become just the fourth Irishman to wear yellow at the Tour de France after his stunning performance into Le Mont-Dore Puy de Sancy. The two-time national champion follows Shay Elliott, Sean Kelly and Stephen Roche in leading the Tour's general classification. He bridged a gap back to 1987 when Roche rode into Paris in yellow to win the Tour — the last Irishman to wear the famed jersey. Fellow Dubliner Elliott was the first to do it — holding the jersey for three days in 1963 after winning a stage into Roubaix to take the race lead. Kelly rode the Tour 14 times between 1978 and 1992, winning five stages and the green jersey on four occasions. But in a glittering career, he only held the Maillot Jaune for just one day. Kelly took the general classification lead after a stage into Pau at the 1983 Tour, but endured a nightmare in the saddle on the next leg to Bagnerés-de-Luchon. The 201km stage covered four mountain passes in the Pyrenees and the Carrick-on-Suir rider suffered on every one of them. 'It was a mountain stage and that was a horrible day for me,' Kelly told me a few years ago. 'It was one of my bad days on the Tour and immediately in the early part I was starting to struggle.' Kelly admitted the pressure and increased media focus of being race leader impacted him that day. Something Healy will have to deal with now as race leader. 'The press come to you and they're asking: 'How long are you going to keep the jersey — do you think you can hold onto it?'' he recalled. 'The tension is building, it does put a certain weight on your shoulders. The motorbikes, the photographers are taking pictures as you're rolling out. 'When you get into the mountains and you get dropped, then of course you have the cameras all around you, showing you starting to lose the jersey. And the TV stays with you for a long time. 'But I wasn't devastated. I think I had experienced that sort of day previously.' To rub salt in the wounds the yellow jersey he wore on the podium in Pau was then stolen from his car after the final stage in Paris. Sam Bennett was the last Irishman to lead one of the Tour's four classifications when he finished the 2020 race in the green jersey. With a rest day on Tuesday, Healy will wear yellow when the peloton departs Toulouse on Wednesday for stage 11 with a 29 second lead ahead of Tadej Pogačar. The 24-year-old also holds the white jersey for the leading young rider. He will be hoping to following in the footsteps of Roche, who came out on top after a titanic battle with Pedro Delgado to become the only Irish winner of the race.
Irish Post
5 days ago
- Entertainment
- Irish Post
Joyce's Dublin comes alive on stage in Volta Theatre's new production
THE Irish Cultural Centre in Hammersmith will host the UK premiere of two compelling stage adaptations from James Joyce's short story collection Dubliners this weekend. Counterparts and A Little Cloud will run at the west London venue today, Friday, July 11 and tomorrow Saturday, July 12. Presented by Volta Theatre Company, the double bill offers an intimate, affecting portrait of early 20th-century Dublin, with live period music enriching the atmosphere. Jim Roche and Liam Hourican star in the Volta Thetre Company production Performed by Jim Roche and Liam Hourican, who also adapted and directed the production, these "slices of life" explore themes of paralysis, yearning, and quiet desperation—hallmarks of Joyce's early work. In Counterparts, a frustrated law clerk spirals into a night of drink-fuelled rage. Farrington, the protagonist, is humiliated by his boss. Unable to assert himself at work, he seeks solace in the pubs of Dublin, drinking heavily and boasting to friends. In the story Joyce paints a bleak portrait of masculine insecurity, paralysis and cyclical abuse. The story is evoked beautifully but disturbingly by Roche and Hourican. In A Little Cloud, a melancholic office worker is stirred to bitterness by a reunion with a more successful friend. Joyce's story follows Little Chandler, a timid Dublin clerk who reunites with his old friend Gallaher, now a worldly journalist living in London. Their meeting triggers Chandler's envy and self-doubt. While Gallaher boasts of his freedom and exploits abroad, Chandler is left brooding over his own constrained life — his poetry ambitions abandoned, his dull routine, and his sense of entrapment in marriage and fatherhood. The double bill opens this evening The show, which recently enjoyed a sell-out run at Bewley's Theatre in Dublin, has been praised for bringing Joyce's characters vividly to life. Irish Times columnist Frank McNally described it as 'a superb dramatised introduction to one of the greatest short-story collections in world literature'. Writing in the Irish Independent, Katy Hayes said the production was 'a delightful pair of stories… beautifully dramatised.' The stories are accompanied by live music from acclaimed Irish musicians Feilimidh Nunan (keyboard and violin) and Conor Sheil (clarinet), both of whom regularly perform with Ireland's leading orchestras and in theatre, film and jazz ensembles. Volta Theatre was founded by Roche and Hourican, long-time collaborators in Irish theatre and television. Hourican's stage credits include the Old Vic and Shakespeare's Globe, while Roche has appeared in Normal People, Harry Wild, The Tudors, Dead Still, and many more. The 60-minute show is suitable for ages 12+. About Dubliners FIRST published in 1914, Dubliners is James Joyce's groundbreaking collection of fifteen short stories depicting ordinary life in the Irish capital at the turn of the 20th century. Written in a spare, realist style, the stories explore themes of paralysis, routine, missed opportunity, and quiet despair — all under the looming shadow of colonialism, religion, and societal expectation. Joyce's characters range from timid schoolboys and worn-out housewives to failed revolutionaries and frustrated civil servants. Despite their modest surroundings and everyday struggles, they are drawn with extraordinary psychological depth. The collection opens with childhood tales like The Sisters and An Encounter, progresses through adolescence and maturity in stories such as A Little Cloud and Counterparts, and culminates in The Dead, widely regarded as one of the finest short stories ever written in English. At the time, Dubliners was considered controversial for its unflinching portrayal of Irish life, and publishers were wary of its frankness. But today it is celebrated for the very qualities that once made it difficult to print: its honesty, precision, and emotional subtlety. With Dubliners, Joyce laid the foundation for modernist fiction — and painted a portrait of Dublin that still resonates more than a century later. The Volta Theatre Company has a resonance with The Volta Electric Theatre Ireland's first dedicated cinema. store. In the early 1900s, demand for moving pictures was fierce and cinemas were springing up all over the world. After living in Trieste, James Joyce was determined to bring cinema to Ireland, so after receiving the backing of his Italian[1] friends, he set up the Cinematograph Volta on Mary Street, Dublin. Counterparts & A Little Cloud, Fri 11 July - Sat 12 July 2025 at Irish Cultural Centre, Hammersmith. Presented by Volta Theatre Company. Running time: 60 minutes | Age guidance: 12+. Click here for tickets.
CNBC
5 days ago
- Business
- CNBC
Trump's 200% tariff threat leaves pharma firms scrambling with scenario planning
The pharmaceutical industry is scrambling with scenario planning as U.S. President Donald Trump's 200% tariff proposal threatens to drive up drug prices and rip out corporate profit margins. The president once again warned on Tuesday that long-awaited industry-wide tariffs would be announced "very soon" after the administration launched a so-called 232 investigation into the sector in April. Trump suggested that those levies would not go into effect immediately, but get a grace period of "about a year, year and a half to come in." Analysts nevertheless warn that such a rate — even with a delay — will have a detrimental effect on drug prices and profit margins. "A 200% tariff would inflate production costs, compress profit margins, and risk supply chain disruptions, leading to drug shortages and higher prices for U.S. consumers," Barclays wrote in a note Wednesday. UBS analysts cited a "significant negative impact" on margins, where goods are manufactured outside of the U.S. Meanwhile, the hit for patients could be "disastrous," Afsaneh Beschloss, founder and CEO of investment firm RockCreek Group said Tuesday, in reference to an estimated 100% levy. "That would be potentially disastrous for every person because we need those pharmaceuticals, and it takes those companies a long time to produce them here in the U.S.," Beschloss told CNBC's "Closing Bell." It is estimated that a tariff of just 25% on pharmaceutical imports would drive up U.S. drug prices by almost $51 billion annually, increasing domestic prices by as much as 12.9% if passed on, according to research from industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA), which on Wednesday lambasted the president's proposals as "counterproductive" to health outcomes. Pharmaceutical products have typically been excluded from trade tariffs due to their critical nature. However, Trump has repeatedly targeted the industry for what he deems unfair pricing practices, and has urged firms to reshore manufacturing to the U.S. In response, global pharma firms — including Novartis, Sanofi and Roche and U.S.-headquartered Eli Lilly and Johnson & Johnson — have made commitments to invest large sums in the U.S. UBS dubbed the administration's tariff grace period of 12 to 18 months as "insufficient time" for firms to relocate their manufacturing stateside. "We would usually think of 4 to 5 years as the timeline to move commercial scale manufacturing to a new site," the analysts wrote. The industry is now awaiting further details at the end of this month, when the final Section 232 investigation report is due. But in the meantime, firms have little choice but to plan for various potential outcomes. A Roche spokesperson said the company was "monitoring the situation closely" and engaging with stakeholders to "advocate for policies that address barriers to patient access" and create "a more equitable and affordable healthcare ecosystem." The Swiss pharmaceutical giant had previously said that Trump's drug pricing order could jeopardize its U.S. investment. However, it noted Wednesday that its proposed funding will allow it to continue building out its manufacturing footprint in the U.S. Bayer similarly said that it was monitoring the "various tariff announcements" and that it was focused on securing its supply chains and "minimizing any potential impact." Novartis, meanwhile, said that it continues to work with the U.S. administration and trade association partners, and that it had "no changes" to its planned U.S. investment. AstraZeneca and Sanofi did not immediately respond to CNBC's request for comment, while Novo Nordisk declined to comment during its pre-earnings quiet period. The pharmaceutical industry had previously sought a sector-wide carve-out from tariffs. But as those hopes have faded, attention is now turning to prospective trade deals as a potential buffer. The U.S.-U.K. trade deal announced last month, while sparse, states that both sides will negotiate "preferential treatment outcomes for U.K. pharmaceuticals and pharmaceutical ingredients contingent on the findings of a Section 232 investigation." Pharma firms in Switzerland and the European Union could be aiming for similar carve-outs in their prospective deals. Yet, without clarity soon, question marks for companies and consumers remain. "The longer this uncertainty reigns over which sectors are going to be affected and which aren't, it's going to have a continuous negative impact," Bert Colijn, chief economist at ING, told CNBC's "Europe Early Edition" on Wednesday.
